BioSpace News Archive

Career paths are not always perfectly linear and uninterrupted. Here are some ways you can display gaps in resumes that don’t appear like a weak point.

No safety issues were cited. Instead, it appears related to the company’s proposal to modify the trial’s analysis plan and various chemistry, manufacturing and controls (CMC) issues.

UnitedHealth Group’s Optum unit is suing David Smith, a former information technology executive, for breach of contract. They note that Smith, in the 18 months before his resignation, played a pivotal role in reviewing Optum’s strategy, and was “one of fewer than 50 people at the company” with access to Optum’s detailed profit-and-loss statements.

Main5 expert panel: Launch medications faster and at lower cost despite stricter formalities

Any 2018 BMS news is going to tend to get lost in the shadow of its $74 billion acquisition of Celgene. Still, it looked like a good year, with fourth-quarter revenue up 10% and full-year revenues up 9%.

San Diego-based Gossamer Bio is pulling the trigger on an initial public offering by harnessing a legal loophole that will allow the company to move forward with its listing plans despite the partial government shutdown, now in its 34th day.

Data to be presented at the 29th Annual IPCU meeting

DiamondTemp Ablation System Represents Disruptive RF Innovation

Vertex fired Chief Operating Officer Ian Smith, who had also been serving as interim chief financial officer since December. The Boston-based company said it promptly launched a comprehensive investigation into the allegations made against Smith with the assistance of an independent external counsel.

Movers and Shakers is BioSpace’s weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.